Allakos Future Growth
Future criteria checks 0/6
Allakos is forecast to grow earnings and revenue by 45.4% and 80.3% per annum respectively while EPS is expected to grow by 54.5% per annum.
Key information
45.4%
Earnings growth rate
54.5%
EPS growth rate
| Biotechs earnings growth | 30.9% |
| Revenue growth rate | 80.3% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 24 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -88 | -100 | N/A | 5 |
| 12/31/2025 | N/A | -76 | -98 | N/A | 7 |
| 12/31/2024 | N/A | -106 | N/A | N/A | 7 |
| 12/31/2023 | N/A | -186 | -117 | -116 | N/A |
| 9/30/2023 | N/A | -166 | -140 | -139 | N/A |
| 6/30/2023 | N/A | -151 | -139 | -136 | N/A |
| 3/31/2023 | N/A | -165 | -142 | -136 | N/A |
| 12/31/2022 | N/A | -320 | -288 | -280 | N/A |
| 9/30/2022 | N/A | -371 | -322 | -299 | N/A |
| 6/30/2022 | N/A | -403 | -350 | -319 | N/A |
| 3/31/2022 | N/A | -411 | -371 | -336 | N/A |
| 12/31/2021 | N/A | -270 | -241 | -208 | N/A |
| 9/30/2021 | N/A | -220 | -195 | -177 | N/A |
| 6/30/2021 | N/A | -199 | -174 | -166 | N/A |
| 3/31/2021 | N/A | -181 | -143 | -142 | N/A |
| 12/31/2020 | N/A | -153 | -115 | -114 | N/A |
| 9/30/2020 | N/A | -134 | -99 | -99 | N/A |
| 6/30/2020 | N/A | -113 | -79 | -79 | N/A |
| 3/31/2020 | N/A | -93 | -69 | -68 | N/A |
| 12/31/2019 | N/A | -85 | -64 | -63 | N/A |
| 9/30/2019 | N/A | -75 | -60 | -57 | N/A |
| 6/30/2019 | N/A | -65 | -55 | -49 | N/A |
| 3/31/2019 | N/A | -55 | -49 | -42 | N/A |
| 12/31/2018 | N/A | -44 | -45 | -38 | N/A |
| 9/30/2018 | N/A | -37 | -38 | -33 | N/A |
| 6/30/2018 | N/A | -32 | -32 | -30 | N/A |
| 3/31/2018 | N/A | -27 | -27 | -26 | N/A |
| 12/31/2017 | N/A | -24 | -23 | -23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 37Z is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 37Z is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 37Z is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 37Z is forecast to have no revenue next year.
High Growth Revenue: 37Z is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 37Z's Return on Equity is forecast to be high in 3 years time